Literature DB >> 30530069

Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.

Carmen Alcalá1, F Pzére-Miralles1, F Gascón1, M Evole1, M Estutia1, S Gil-Perotín1, B Casanova1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30530069     DOI： 10.1016/j.msard.2018.12.005

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  3 in total

1.  Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital.

Authors:  Rocío López Ruiz; Félix Sánchez Fernández; María Ruiz de Arcos; Julio Dotor García-Soto; Alejandro Fuerte Hortigón; Guillermo Navarro Mascarell; Juan Luis Ruiz Peña; M Dolores Páramo Camino; Juan Diego Guerra Hiraldo; Sara Eichau
Journal:  Neurol Clin Pract       Date:  2022-02

2.  Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.

Authors:  Mokshal H Porwal; Amber Salter; Dhruvkumar Patel; Ahmed Z Obeidat
Journal:  J Cent Nerv Syst Dis       Date:  2022-06-23

3.  Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: A case report.

Authors:  Laura D Chin; Mohn'd AbuHilal
Journal:  SAGE Open Med Case Rep       Date:  2020-05-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.